{"entity":{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","aka":[],"tldr":"Marker grows a patient's own T cells that naturally recognise several tumour proteins at once, without genetic engineering, and gives them back as a treatment. Its lead product has shown responses in relapsed lymphoma and is moving into pancreatic cancer.","summary":"Marker Therapeutics is a Houston clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies, non-engineered T-cell products enriched for reactivity against several tumour-associated antigens. Lead candidate MT-601 is in the phase 1 APOLLO study in relapsed non-Hodgkin lymphoma, where an update reported a 66% objective response rate including 50% complete responses; lymphodepletion was shown to enhance MT-601 expansion and persistence, and the study moved into dose expansion in relapsed diffuse large B-cell lymphoma with a further update expected in the second quarter of 2026. Baylor College of Medicine research published in Nature Medicine in early 2026 reported promising results with MAR-T cells in pancreatic cancer, and Marker plans a company-sponsored pancreatic cancer trial. Manufacturing is supported by a collaboration with Cellipont Bioservices. Nasdaq: MRKR.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://markertherapeutics.com/"},{"label":"Year-end 2025 results (8-K exhibit 99.1, March 2026)","url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_ex99-1.htm"}],"tags":[],"related":[],"cancers":["dlbcl","pancreatic"],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Houston, TX","country":"US","companyType":"cell-therapy","website":"https://markertherapeutics.com/","ticker":"MRKR","stage":"public","investors":[],"funding":[]},"route":"/companies/marker-therapeutics/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}]}}